SCHEDULE: BVF Funds Maintain 5.2% Stake in Cidara Therapeutics
Beneficial Ownership Report (Schedule 13G Amendment)
BVF Partners and affiliated entities report a combined 5.2% beneficial ownership in Cidara Therapeutics, Inc. as of September 30, 2025.
Summary
- BVF Partners L.P. and its affiliates, including Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS LP, collectively hold a significant stake in Cidara Therapeutics, Inc.
- As of September 30, 2025, the aggregate beneficial ownership by BVF Partners L.P., BVF Inc., and Mark N. Lampert is 1,414,165 shares, representing approximately 5.2% of the outstanding common stock.
- This ownership includes shares held by Biotechnology Value Fund L.P. (729,856 shares or 2.7%), Biotechnology Value Fund II, L.P. (578,633 shares or 2.1%), and Biotechnology Value Trading Fund OS LP (77,407 shares or 0.3%).
- The calculation of outstanding shares for percentage determination includes 25,358,051 shares as of August 6, 2025, plus 280,865 shares from warrant exercise, 487,603 shares from Series X Preferred Stock conversion, and 1,039,990 shares from Series A Preferred Stock conversion, all issued on August 18, 2025.
Sentiment
Score: 6
Explanation: The filing indicates a significant institutional investor, BVF Partners, maintains a substantial stake in Cidara Therapeutics, which is generally a positive signal of investor confidence. The explicit statement against seeking control also reduces potential concerns about activist pressure, though the mention of 14a-11 nominations adds a slight nuance.
Positives
- A prominent biotechnology-focused investment fund, BVF Partners, maintains a significant 5.2% stake, indicating continued investor confidence.
- The securities were not acquired for the purpose of changing or influencing control of the issuer, which can reduce concerns about activist investor pressure.
Risks
- The reporting persons certify that the securities were not acquired for the purpose of changing or influencing control, except for activities solely in connection with a nomination under Rule 14a-11, which could imply potential future engagement in director nominations.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding future performance or strategic plans.
Industry Context
In the biotechnology sector, institutional investor holdings, particularly by specialized funds like BVF Partners, are closely watched as they can signal confidence in a company's drug pipeline or strategic direction. Maintaining a significant stake suggests a continued belief in Cidara Therapeutics' long-term prospects within the competitive biotech landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Statement of Intent | The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11. | 2025-09-30 | This statement clarifies the investor's passive intent, reducing immediate concerns about hostile takeovers, but leaves open the possibility of future engagement in director nominations. |
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional investor's continued stake can provide a level of confidence and transparency regarding the company's ownership structure.
Key Dates
| Date | Description |
|---|---|
| 2025-08-06 | Date of outstanding shares reported in Issuer's Quarterly Report on Form 10-Q. |
| 2025-08-07 | Date Issuer's Quarterly Report on Form 10-Q was filed with the Securities and Exchange Commission. |
| 2025-08-18 | Date of issuance of 280,865 shares from pre-funded warrant exercise, 487,603 shares from Series X Convertible Preferred Stock conversion, and 1,039,990 shares from Series A Convertible Preferred Stock conversion to the Reporting Persons. |
| 2025-09-30 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-10-17 | Date of filing of this Schedule 13G Amendment No. 9. |
Recommendation
holdThe filing is a routine disclosure of beneficial ownership by a significant institutional investor. While maintaining a 5.2% stake by BVF Partners is a positive signal of continued confidence, the filing itself does not contain new operational or financial performance data to warrant a change in investment recommendation. It primarily confirms an existing substantial position.
Keywords
Cidara Therapeutics, CDTX, Beneficial Ownership, Schedule 13G, BVF Partners, Biotechnology Value Fund, Institutional Investor, Common Stock, SEC Filing, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.